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Aggregation of the pre-synaptic protein, α-synuclein (α-syn), is the key etiological factor
in Parkinson’s disease (PD) and other alpha-synucleinopathies, such as multiple system
atrophy (MSA) and Dementia with Lewy bodies (DLB). Various triggers for pathological
α-syn aggregation have been elucidated, including post-translational modifications,
oxidative stress, and binding of metal ions, such as calcium. Raised neuronal calcium
levels in PD may occur due to mitochondrial dysfunction and/or may relate to calcium
channel dysregulation or the reduced expression of the neuronal calcium buffering
protein, calbindin-D28k. Recent results on human tissue and a mouse oxidative stress
model show that neuronal calbindin-D28k expression excludes α-syn inclusion bodies.
Previously, cell culture model studies have shown that transient increases of intracellular
free Ca(II), such as by opening of the voltage-gated plasma calcium channels, could
induce cytoplasmic aggregates of α-syn. Raised intracellular free calcium and oxidative
stress also act cooperatively to promote α-syn aggregation. The association between
raised neuronal calcium, α-syn aggregation, oxidative stress, and neurotoxicity is
reviewed in the context of neurodegenerative α-syn disease and potential mechanism-
based therapies.
Keywords: Parkinson’s disease, α-Synuclein, calcium, Multiple system atrophy, Dementia with Lewy bodies
INTRODUCTION: α-SYNUCLEIN IN NEURODEGENERATION
α-Synuclein (α-syn) is a small (14 kDa), acidic protein that is highly conserved in vertebrate
species. It is primarily expressed in the presynaptic terminals of dopaminergic neurons
in the olfactory bulb, frontal cortex, striatum, and the hippocampus. α-Syn has also
been observed in hypothalamus, thalamus, midbrain, cerebellum, and the pons/medulla
oblongata with lower expression (Maroteaux et al., 1988; Iwai et al., 1995; Clayton and
George, 1999). The normal function of α-syn remains unknown, however, it has been
found that α-syn can interact with the lipid bilayer of neurons to prevent SNARE-
mediated fusion of vesicles (DeWitt and Rhoades, 2013). Cytoplasmic and nuclear inclusion
bodies containing α-syn have been found throughout the central nervous system (CNS) in
Abbreviations: α-syn, α-synuclein; CB, Calbindin D28K; CBP, Calcium buffering protein; CNS, Central nervous system;
CR, Calretinin; DLB, Dementia with Lewy bodies; ER, Endoplasmic reticulum; GC, Glial cytoplasmic inclusion; JNK, c-
jun N-terminal kinase; LBs, Lewy bodies; MSA, Multiple system atrophy; NCX, Na(I)-Ca(II) exchanger; PD, Parkinson’s
disease; PMCA, Plasma membrane Ca(II) ATPase; PV, Parvalbumin; SNpc, Substantia nigra pars compacta; ROS, Reactive
oxygen species; TMO, Trimethadione; VDCC, Voltage-dependent calcium channel; SERCA, sarco/endoplasmic reticulum
Ca2+-ATPase.
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a number of neurodegenerative disorders. These are collectively
termed α-synucleinopathies and include Parkinson’s disease (PD)
and atypical PD, such as multiple system atrophy (MSA) and
Dementia with Lewy bodies (DLB; Goedert et al., 2013; Eschbach
and Danzer, 2014; Radford et al., 2014). Aggregation of α-syn
results from dynamic instability of the native structure and may
be promoted by gene mutations or by environmental stressors,
such as oxidative stress or metal ion concentration changes.
PD can be classified into two main groups: idiopathic PD,
accounting for 85–90% of all PD cases; and familial PD,
accounting for 10–15%. Currently, six PD-linked mutations
in PARK1/4, the α-syn gene, have been identified that may
provide important clues to the pathways that may give rise to
idiopathic PD. They include the A30P (Kruger et al., 1998),
A53T (Polymeropoulos et al., 1997), E46K (Zarranz et al., 2004),
H50Q (Proukakis et al., 2013), A53E (Pasanen et al., 2014), and
G51D (Lesage et al., 2013) amino acid substitutions that disrupt
FIGURE 1 | (A) α-Synuclein (α-syn) protein domain structure. KTK repeats in the N-terminus are involved in lipid interaction, the hydrophobic NAC domain is
important for aggregation and the C-terminal Ca(II) binding site can increase the rate of oligomerization (Nielsen et al., 2001; Lowe et al., 2004). Parkinson’s disease
linked point mutations are indicated within the neurotransmitter vesicle binding domain. (B) Neuronal Calbindin-D28K (CB), inhibits α-syn inclusion bodies in DLB and
mouse model tissue (Rcom-H’cheo-Gauthier et al., 2016). (B1-2) Dementia with Lewy bodies immunofluorescence for α-syn (green) and CB (red, arrow) showing rare,
small cytoplasmic α-syn aggregates (arrowhead) in a CB+ neuron and a typical, large perinuclear α-syn inclusion body in a CB- neuron. (B3-4) Rotenone lesioned
mouse (oxidative stress) model shows a similar pattern of large perinuclear α-syn inclusion bodies that are absent from CB expressing neurons, with only small α-syn
puncta rarely detected in CB positive cells; scale bar 5 µm.
the membrane binding domain (Figure 1A). The A53T and
A30P mutations also alter neuronal cytotoxicity in response to
hydrogen peroxide and 1-methyl-4-phenylpyridinium (MPP+)
treatment. Expression of these mutant isoforms significantly
increased cytotoxicity in comparison to cells expressing wild-
type (WT) α-syn, which was similar to control cells (Kanda
et al., 2000). Furthermore, both mutations showed increased
fibril formation compared to WT (Conway et al., 1998, 2000;
Narhi et al., 1999). E57K: mThy-1 human α-syn transgenic
mice with increased oligomerisation of α-syn had decreased
vesicles, synapse, and neuron degeneration in comparison to
wildtype controls and E57K mice expressing lower levels of
α-syn (Rockenstein et al., 2014). Gene duplication (Chartier-
Harlin et al., 2004; Ibanez et al., 2004) and triplication of α-
syn (Singleton et al., 2003) has also been found in familial
PD, implicating increased expression of the wild-type protein.
Recasens et al. (2014) have demonstrated that α-syn species
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found in PD-derived Lewy bodies (LBs) were pathogenic and
had the capacity to initiate a PD-like pathological process.
This included intracellular and presynaptic aggregation of
pathological α-syn species in various parts of the brain and
progressive cell loss of dopaminergic neurons. Several metals
have been implicated in the aggregation of α-syn, including,
iron, manganese, copper, and zinc (Santner and Uversky, 2010;
McAllum and Finkelstein, 2016). However, this review will
focus on calcium in alpha-synucleinopathies and its interaction
with α-syn.
VOLTAGE-GATED Ca(II) CHANNELS IN
NEURODEGENERATION
Homeostatic Ca(II) regulation is essential to the health and
functioning of cells. Although N-type voltage-gated Ca(II)
channels (Cav) are the primary regulators of Ca(II) influx
and corresponding neurotransmitter release in neurons (Simms
and Zamponi, 2014), various studies highlight the broader
range of Ca(II) channels found throughout the CNS. There
are three types of Cav expressed in the brain, Cav1, Cav2, and
Cav3 (Catterall et al., 2005), comprising four Cav1 subtypes
(L-type configuration), three types of Cav2 channels (P/Q, N,
and R configuration), with Cav2.1 and Cav2.2 responsible for
neurotransmitter release, and the family of low-voltage activated
T-type channels, Cav3.1, Cav3.2, and Cav3.3 (Talley et al.,
1999; Heady et al., 2001; Catterall et al., 2005). Inhibition
of Cav1, 2.1, and 2.2 channels have each been shown to
decrease neuronal damage upon brain injury (Perez-Pinzon et al.,
1997; Babu and Ramanathan, 2011; Kim et al., 2016), which
also leads to increased α-syn expression, α-syn aggregation,
and Parkinson’s-like pathology (Acosta et al., 2015). Cav3
contribute to the pathogenesis of epilepsy (Chemin et al.,
2001), and have also been reported in glial cells (Yunker
et al., 2003). Bassoon, a neuronal zinc finger pre-synaptic
scaffold protein shows increased expression in MSA cerebellum
(Hashida et al., 1998). Interestingly, Bassoon increased Cav2.1
expression, associated with a longer calcium transient, when
over-expressed and decreased Cav2.1 when knocked out in
an epilepsy model (Davydova et al., 2014; Ivanova et al.,
2015). Moreover, pathological α-syn species may mediate
calcium entry and thus both further promote calcium-dependent
α-syn aggregation and directly lead to calcium-dependent
cytotoxicity (Angelova and Abramov, 2016). Wildburger et al.
(2009) investigated the neuroprotective properties of the Ca(II)
channel blocker, trimethadione (TMO), in cultured hippocampal
and cortical neurons from C57BL/6 and α1H−/− mice,
showing a significant decrease in cell death following TMO
treatment (Wildburger et al., 2009). Moreover, Follett et al.
(2013) showed that SH-SY5Y cells subjected to membrane
depolarization by potassium resulted in Ca(II) influx and
α-syn-positive cytoplasmic aggregates that could be blocked
by TMO pre-treatment. Furthermore, Danish subjects taking
dihydropyridine L-type calcium channel blockers between 1995
and 2006 were 27% less likely to develop PD (Ritz et al., 2010;
Pasternak et al., 2012). Following this, a Phase II tolerability
trial in early stage PD patients was conducted and found that
isradipine was well-tolerated (Parkinson Study Group, 2013).
Ca(II) REGULATION IN AGEING AND
NEURODEGENERATION
Regulation of calcium homeostasis requires a complex interplay
between the cytoplasmic channels/pumps and intracellular Ca(II)
stores, such as the mitochondria and endoplasmic reticulum
(ER), andmay be affected by age (Toescu andVerkhratsky, 2007).
It has been established that resting intracellular Ca(II) levels
remain the same despite the age of the neuron. However, the
return time to resting levels is significantly increased in aged
neurons after a stimulus. Aged neurons also exhibit a decreased
capacity to recover from Ca(II) stimulus through uptake into the
intracellular Ca(II) stores with a decline in sarco/endoplasmic
reticulum Ca(II)-ATPase (SERCA) function (Pottorf et al., 2000).
Moreover, Ca(II) pumping into the extracellular space via the
plasma membrane Ca(II) ATPase (PMCA) has been shown
to be impaired in aged neurons (Michaelis et al., 1996). The
calcium buffering capacity of neurons was also shown to be
decreased in aged neurons and some studies have shown that
after stimulation, the concentration of Ca(II) may be decreased,
but the recovery time back to resting levels is dramatically
increased (Duckles et al., 1996). Calbindin D28K (CB), calretinin
(CR), and parvalbumin (PV) are three cytosolic Ca(II) buffering
proteins (CBP) that are capable of Ca(II) buffering in neurons
and belong to the EF-hand protein family. The other CBP
family is the annexin family and is characterized by proteins
that bind Ca(II) in the presence of phospholipids-containing
membranes (Andressen et al., 1993). The EF-hand proteins
may function either as Ca(II) buffers, decreasing the free
cytoplasmic concentration, or as triggers starting a cascade of
responses (Dalgarno et al., 1984). The ubiquitous trigger protein
calmodulin activates at least 20 different enzymes, while PV,
CB, and CR, are more passive buffers decreasing the amplitude
of Ca(II) signals. In a human study conducted by Bu et al.
(2003), a decrease was found in both CR and CB in aged
compared to young cortical neurons, but no difference in PV
positive neurons. Yamada et al. (1990) found that dopaminergic
neurons of the Substantia nigra pars compacta (SnPc) that were
high in CB were preferentially spared in control brain sections
compared with PD patients. The importance of these proteins
has also been implicated by German et al. (1992) who studied
the brains of human patients with PD, MPTP monkey or in
C57BL/6. They found that in both idiopathic PD and in the above
models, neurons that contained CB were spared while neurons
in CB-negative (CB-) regions were lost. Gaspar et al. (1994)
found that dopaminergic neurons expressing CB were spared
from loss in a mouse model with Parkinsonian-like pathological
features. Tsuboi et al. (2000) and Kim et al. (2000) found that
CR expression in dopaminergic neurons of the SnPc were more
protected against 6-hydroxydopamine (Kim et al., 2000; Tsuboi
et al., 2000). Moreover, a recent study has described the over-
representation of CB-positive (CB+) neurons in DLB, and the
almost complete exclusion of α-syn aggregates in CB+ neurons.
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This study draws the same conclusions in a rotenone (oxidative
stress) mousemodel of α-synucleopathy (Rcom-H’cheo-Gauthier
et al., 2016). In both DLB and the mouse model, occasional
neurons with low CB expression showed small α-syn aggregates,
but large perinuclear inclusion bodies were only detected in CB-
cells (Figure 1B; Rcom-H’cheo-Gauthier et al., 2016).
INCREASED INTRACELLULAR Ca(II)
INDUCES α-SYNUCLEIN
OLIGOMERISATION
Nielsen et al. (2001) first demonstrated that Ca(II) binding to α-
syn regulates ligand binding and oligomerization. Subsequently,
Lowe et al. (2004) found that calcium promoted α-syn annular
oligomer formation that required the C-terminal calcium
binding site (Figure 1A). The α-syn C terminus contains a
sequence of six negatively charged acidic amino acids similar
to an EF-hand-like motif (Zhou et al., 2006), although more
studies are required to precisely delineate the calcium binding
residues. More recent studies have shown that by increasing
free intracellular Ca(II) concentration thapsigargin or Ca(II)
ionophore chemical treatments caused a significant increase
in the proportion of cells bearing microscopically-visible α-
syn aggregates. It was also demonstrated that co-treatment
with intracellular Ca(II) chelator, suppressed the aggregation,
indicating that α-syn aggregation was induced by raised
intracellular free Ca(II) directly, although a possible role for
calpain protease activation could not be excluded. Moreover,
supporting studies with recombinant α-syn indicated that direct
binding of Ca(II) ion to α-syn promoted rapid oligomer
formation in vitro (Nath et al., 2011). More recently, Follett
et al. (2013) demonstrated that depolarization of the plasma
membrane resulted in raised intracellular free Ca(II) and α-syn
aggregation triggering the formation of large LB-like perinuclear
α-syn inclusion bodies after 48 h that could be inhibited both
by Ca(II) chelation and calcium channel blockade (Follett et al.,
2013). Moreover, Chan et al. (2007) assessing Ca(II) blockade
using brain slices from a MPTP mouse model of PD determined
that the L-type Cav1.3 Ca(II) channel inhibitor, Isradipine, a drug
used to treat high blood pressure, could recover dopaminergic
neural activity. Furthermore, Singh et al. (2016) also used
an L-type calcium channel blocker, nimodipine, in the same
model and observed reduced loss of TH positive neurons and
reduced reactive oxygen species (ROS) production in the striatal
mitochondria.
OXIDATIVE STRESS AND α-SYNUCLEIN
OLIGOMERIZATION
Another potential target for α-synucleinopathy therapeutics
could be to target oxidative stress in the brain. There is evidence
that oxidative stress is increased in the normal aged brain,
however the level of oxidative stress is greatly increased in
patients with neurodegenerative diseases (Sims-Robinson et al.,
2013). Thus, WT α-syn has been shown to induce mitochondrial
NO when it is associated with mitochondria (Parihar et al.,
2008). This indicates that not only will normal increases in
oxidative stress cause aggregation but that aggregation of α-
syn also induces more oxidative stress within the cell forming
a positive feedback loop. Moreover, other research shows that
α-syn protects cells from oxidative stress by deactivating the
c-jun N-terminal kinase (JNK) pathway, although this data
was from cells challenged with exogenous H2O2 (Hashimoto
et al., 2002). The combination of oxidative stress and α-syn
expression has been used to generate a model of MSA in
mice, whereby the over-expression of α-syn in glial cells is
combined with 3-nitropropionic acid. Treatment to induce
mitochondrial oxidative stress was sufficient to induce MSA like
pathology (Ubhi et al., 2009). Moreover, Kume et al. (2012)
found urinary 8-OHdG levels were significantly higher in DLB
cases compared to controls, indicating systemically increased
oxidative stress. Oxidative stress in aging primates originates
primarily from mitochondrial complexes I and III of the electron
transport chain which leads to greater mitochondrial DNA
damage compared to nuclear DNA (Castro Mdel et al., 2012).
Indeed, widespread mitochondrial DNA damage occurs at early
stages of DLB (Lin et al., 2012). Moreover, α-syn oligomers
promoted Ca(II)-inducedmitochondrial dysfunction (Luth et al.,
2014) and oxidative stress characterized by α-syn lipoxidation
precedes the formation of α-syn aggregates and the development
of neocortical LB pathology in DLB (Dalfo and Ferrer, 2008).
Furthermore, Quilty et al. (2006) showed that when mouse
primary neocortical cells were incubated in the absence of
antioxidants, mild oxidative stress caused α-syn accumulation
in a subset of neurons. Indeed, recent studies have found the
oxidized form of the endogenous oxidative stress sensor, DJ-
1, progressively increased in the later stages of PD and more
highly oxidized forms were likely present in DLB (Saito et al.,
2014). Furthermore, it has been demonstrated that Ca(II) influx
can interact with α-syn to mediate increased oxidative stress
(Dryanovski et al., 2013; Surmeier et al., 2016). Indeed, the
combination of oxidative stress and raised intracellular free
Ca(II) showed a synergistic effect on α-syn aggregation (Goodwin
et al., 2013). More recently, α-syn aggregation was studied
using an oxidative stress mouse model where unilateral lesion
was performed using the mitochondrial complex I inhibitor,
rotenone. The results showed an increase in α-syn aggregates
in the lesioned hemisphere, compared to sham or unlesioned,
especially in aged animals, combined with an exclusion of α-syn
aggregates from CB-expressing neurons, further implicating a
cooperative interaction between calcium buffering and oxidative
stress (Rcom-H’cheo-Gauthier et al., 2016).
α-SYNUCLEIN AGGREGATION, RAISED
Ca(II), AND OXIDATIVE STRESS
Hettiarachchi et al. (2009) demonstrated that elevated levels of
intracellular α-syn elevated levels of intracellular Ca(II), although
reduced Ca(II) was observed in primary neurons overexpressing
α-syn when treated with manganese (Ducˇic´ et al., 2015).
Furthermore, secreted α-syn induced an increase in capacitive
Ca(II) entry in differentiated SH-SY5Y cells (Melachroinou et al.,
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FIGURE 2 | Multiple interactions of Ca(II) and oxidative stress on α-syn aggregation. Elevated levels of intracellular Ca(II) may cause α-syn aggregation and
the formation of LBs. This calcium dysregulation could be mediated by elevated reactive oxygen species (ROS) and/or calcium mobilization from mitochondria, α-syn
oligomer pores or dysregulation of voltage-dependent calcium channel (VDCC), plasma membrane Ca(II) ATPase (PMCA), or Na(I)-Ca(II) exchanger (NCX).
2013). Transmembrane entry of Ca(II) or other cations may be
via α-syn pore-like oligomers (Pountney et al., 2005; Mironov,
2015) and can mediate cytotoxicity (Angelova et al., 2016).
Transgenic mice over-expressing human WT α-syn showed
that α-syn transgenic mice exhibited augmented, long-lasting
Ca(II) transients characterized by considerable deviation from
the exponential decay. Furthermore control and α-syn knock
out groups demonstrated low percentages of neurons with Ca(II)
abnormalities whereas the α-syn transgenic group showed Ca(II)
response alteration, suggesting these alterations are related to
α-syn expression (Reznichenko et al., 2012; Mironov, 2015).
Furthermore, Navarria et al. (2015) showed that overexpression
of α-syn reduced NMDAR-mediated Ca(II) influx.
Cali et al. (2012) observed significantly greater levels of
mitochondrial Ca(II) in α-syn treated cells compared to
control cells. In SH-SY5Y and HeLa cells, ER-mitochondria
interactions and increased mitochondrial Ca(II) were enhanced
by overexpressed α-syn and increased mitochondrial Ca(II)
transient. Moreover, treatment with native α-syn increased
Ca(II) entry in primary rat cortical neurons and induced
mitochondrial Ca(II) uptake. Dryanovski et al. (2013) found
that in dopaminergic neurons bearing inclusions, ROS levels
in the mitochondria were greater in the soma and proximal
dendrites than in neurons not bearing any inclusions. Treatment
with isradipine significantly reduced the ROS levels in CB−
dopaminergic neurons when compared to CB+ dopaminergic
neurons, suggesting ROS production in the cytosol is triggered
by the formation of α-syn inclusions. Buttner et al. (2013)
established that α-syn leads to elevated cytosolic Ca(II) in yeast
that coincides with an increase in oxidative stress. This suggests
that the formation of α-syn aggregates triggers an increase in
mitochondrial Ca(II) transient and then leads to oxidative stress.
WT α-syn also displayed the capacity to induce mitochondrial
NO when associated with mitochondria (Parihar et al., 2008)
and oxidative stress induced by Ca(II) influx was worsened in a
DJ-1 mutant mouse PD model (Goldberg et al., 2012). Thus, an
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increase in oxidative stress can cause α-syn aggregation and that
aggregation can also induce further oxidative stress within the
cell forming a positive feedback loop. Though, this contradicts
other research by Hashimoto et al. (2002) which shows that α-
syn protects cells from oxidative stress by inactivating the JNK
pathway. More recently, the antioxidant capacity of SH-SY5Y
cells was shown to be decreased by changes in SOD1 and SOD2
enzyme activity and decreased gluthathione levels following
overexpression of α-syn (Perfeito et al., 2016). Koch et al. (2016)
also found that α-syn fibrils increase SOD1 aggregation in vitro
and in vivo.
Recent findings indicate that oxidative stress and increased
intracellular free Ca(II) synergistically increased the number of α-
syn-positive aggregates (Goodwin et al., 2013). Moreover, in vitro
experiments demonstrated that Ca(II) binding alone was able
to induce non-stable α-syn aggregates, whereas, co-treatments
with Ca(II) and oxidant resulted in the formation of larger,
stable aggregates. Furthermore, kinetic experiments of α-syn
aggregate formation by Nath et al. (2010) were consistent with
an auto-catalytic mechanism. Thus, Ca(II)/oxidation stabilized
α-syn aggregates could in turn serve to increase nucleation
centers in disease. This is supported by work performed by
Krishnan et al. (2003) that show that oxidatively di-tyrosine cross
linked α-syn dimers were the rate limiting step in the fibrillation
process in forming nucleation centers. Moreover, Ca(II) influx
into neurons can induce oxidative stress that may in turn result
in further α-syn aggregation. Figure 2 summarizes the potential
synergies between raised calcium levels, oxidative stress, and
α-syn aggregation.
CONCLUSION: CHALLENGES FOR
FUTURE THERAPEUTICS
Calcium channel antagonists are currently undergoing clinical
trials for PD therapy, however many of these drugs may
display undesirable features when used chronically. Modulating
neuronal calcium homoeostasis via endogenous CBP or through
differential calcium channel recruitment could offer efficient
alternatives.
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